Fitish Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 6.5/10
Best for: a flat all-in monthly price on compounded GLP-1 shots or tablets
Fitish falls below our bar on oversight: the FDA has issued it a warning letter. Its compounded semaglutide costs $219 a month, 10% above the $199 median among the sellers we compare.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Prices checked October 2026
Fitish is a clean-beauty brand that added telehealth. Its compounded semaglutide with B6 costs $219 and compounded tirzepatide $339 for a monthly supply, with the provider consult and shipping included. An oral tirzepatide tablet also costs $339 a month. A separate microdose program at $179 or $269 per 28 days is sold as cosmetic support, not weight loss.
Is Fitish legit?
Fitish is a real, operating US company, and the FDA has issued it a warning letter. The letter is summarized at the top of this review. Read what it alleges before you decide, and raise it with the clinician who would prescribe for you. We rate Fitish 6.5/10 overall.
Is there a Fitish promo or coupon code?
We know of no promo or coupon code for Fitish. Its listed price is $219 a month. Coupon sites advertising "Fitish discount codes" are not a source we can vouch for, and any genuine offer shows at checkout without a code.
See how Fitish compares on our rankings of the best semaglutide providers and the best tirzepatide providers.
Vetted alternatives to Fitish
Collective
Best for: flat any-dose pricing, if you can absorb a $199 annual membership on top
Editorial score · methodology
Embody
Best for: a flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
Editorial score · methodology
Luvo Health
Best for: moving between compounded and brand without changing seller
Editorial score · methodology
Fitish at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $219/mo
- What's included
- Medication · Consult · Shipping
- FDA status
- 1 FDA warning letter (details below)
How Fitish scores
Six columns, each one computed from something Fitish has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where a seller keeps something back, such as its price or its pharmacy, the score reflects it. Every seller we review goes through the same six columns.
Value25%
4.3/10$219/month is 10% above the $199 median for compounded semaglutide across the sellers we compare.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10A price is shown before the questionnaire starts.
Trust & Safety15%
3.5/10The FDA has issued it a warning letter. No pharmacy is named for its prescriptions. It shows a price before asking for health information.
Accessibility10%
5.0/10No state list is available to check, so this is held at the midpoint rather than scored on reach.
Support10%
7.0/10The price covers the medication, clinician visits and shipping.
A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →
What we checked on Fitish
Last checked October 2026- Checked the listed price across 3 dose or plan tiers
- Checked what the monthly price covers, and what it leaves out
- Checked FDA warning letters for Fitish
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below.
What signing up with Fitish involves
What to expect on the way to a prescription: where the price appears, who fills the medication, and what the monthly price covers. It is not medical advice, and a clinician makes the prescribing decision.
- 1Fitish shows a price on its own site before asking anything about you, so you can compare it with other sellers before you start a questionnaire.
- 2Ask Fitish which pharmacy fills the prescription before you pay. The pharmacy's name is what lets you check its license.
- 3The monthly price includes the medication, clinician visits and shipping.
- Lowest ongoing monthly price: semaglutide $219, tirzepatide $339. That leaves out membership fees, first-month rates and insurance copays.
- Confirm that Fitish serves your state before you start.
- The FDA has issued Fitish a warning letter. It is covered in the enforcement section below; read what it alleges before you decide.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
Medications Fitish lists
Fitish lists compounded semaglutide and compounded tirzepatide. Each one has its own guide: how it works, the dosing schedule, the side effects that show up in practice, and what the trials measured.
Pricing
Prices re-verified
Daily tablet. No FDA-approved oral tirzepatide exists.
Check the price yourself before you pay
Every figure here comes from Fitish's own website, as of the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication, clinician visits and shipping
Against it
- Semaglutide costs $219 a month, 10% above the $199 median for compounded semaglutide across the sellers we compare
- Tirzepatide costs $339 a month, 26% above the $269 median for compounded tirzepatide across the sellers we compare
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- The FDA has issued Fitish a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Fitish charges
Fitish lists $219/month.
- Compounded semaglutide: $219/month
- Compounded tirzepatide (injection): $339/month
- Compounded tirzepatide (tablet): $339/month
For compounded semaglutide, the median across the sellers we compare is $199/month, so Fitish's $219 lands mid-market. Price is unlikely to be the deciding factor.
Belle Health dispenses semaglutide and tirzepatide from $199/month, which makes it the fair comparison to run before you commit here.
What Fitish dispenses
Fitish prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. The medication is compounded rather than dispensed as an approved pen. Compounding serves real clinical needs and is entirely lawful; what it is not is reviewed, and the cost difference reflects that. The molecule can be the one in Ozempic and Wegovy; what differs is the formulation, the concentration and the dose ladder.
A needle-free oral option is genuinely uncommon and is the reason some readers will look at Fitish at all. Set expectations on the evidence, though: the published weight-loss trials for these molecules used injections. Oral and sublingual delivery of peptides is far less studied, so treat it as a route that solves the needle problem rather than as a proven equal to the shot.
Safety and disclosure
Fitish tells you its price before you start the medical questionnaire. The FDA has issued Fitish a warning letter, summarized at the top of this page. A letter flags a problem rather than ruling a seller out, so read what it says before deciding what it means for you. Because the medication is compounded, the most useful question to ask at intake is which licensed pharmacy fills the prescription. If Fitish will not tell you, treat that as a warning sign. Across the market, the FDA's GLP-1 warning letters are mostly about what sellers said rather than what pharmacies made. How we weigh oversight, disclosure and price is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Everything listed here is compounded.
- You need insurance to cover the cost. Check whether Fitish bills your plan before you start.
- A seller's regulatory history matters to you more than price. Read the warning letter summarized above before deciding.
It fits if
- injections are the thing keeping you from starting
Our read
Fitish lands mid-market on price. The catch is disclosure, which is why Fitish scores low on Trust & Safety: settle the pharmacy and pricing questions above before the price decides for you. Whatever you decide, read the warning letter summarized at the top of this page first, and raise it with the clinician who would prescribe for you.
The Bottom Line
Fitish falls below our bar on oversight: the FDA has issued it a warning letter. Its compounded semaglutide costs $219 a month, 10% above the $199 median among the sellers we compare.
Before you pay Fitish
Starting at $219 a month. Check today's price, then start the intake.
Where Fitish is the wrong choice
No seller suits every reader, and pretending otherwise is the easiest way to sell one. On these three counts, another seller does better.
- If you need the FDA-approved pen rather than a compounded vial, consider WellMedRx.
- If the standing monthly cost is what decides it, consider Collective (from $59/mo + membership).
- If you want a human checking in, not just a prescription, consider Eden.
If none of these fits, our guide to alternatives to Fitish sets more sellers in the same category beside Fitish on price, states and what the price includes.
Frequently Asked Questions
How to check Fitish yourself
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Regulatory notice
Fitish has an FDA warning letter on record, dated June 8, 2026
This letter concerns false & misleading claims/misbranded (telehealth). A warning letter is public correspondence from FDA, not an adjudication. On its own it establishes no finding of illegal activity, and a company that gets one often answers with corrective action.
Sources
Cited across this Fitish review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of October 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.
See Fitish's current pricing
Plans start at $219 a month. Whether you qualify is a clinician's decision, made after your intake.